The discovery of active compounds with novel skelecton is a great challenge for modern medicinal chemistry. It can not only improve the efficacy and drug-like properties of molecules, but also help pharmaceutical companies break patent barriers and build core competitiveness. Skeleton transition is a commonly used strategy for exploring novel skeleton, which usually starts from known compounds to find compounds with similar activities but with different core structures. I wonder what benefits are there for Skeleton Discovery and Screening.
